Abstract-We screened 100 patients with inherited and sporadic lower motor neuron degeneration and identified three novel missense mutations in the glycyl-tRNA synthetase (GARS) gene. One mutation was in the anticodon binding domain and associated with onset in early childhood and predominant involvement of the lower limbs, thus extending the phenotype associated with GARS mutations. There is considerable clinical and genetic overlap between subtypes of inherited neuropathy. 1 Mutations in the glycyl-tRNA synthetase (GARS) gene have been found in families with Type V (upper limb predominant) autosomal dominant distal hereditary motor neuropathy (HMN)/spinal muscular atrophy (SMA), and also in Charcot-Marie-Tooth disease (CMT) Type 2D, in which there is similar distribution of weakness but additional evidence of sensory involvement.
Results. We identified three novel mutations.
Family 1: G598A (2313g¡c). The proband was born at full term by uncomplicated vaginal delivery to unrelated parents with no family history of weakness. Early motor milestones were normal, achieving head control at age 3 months and sitting unaided at 6 months. However, her parents noticed at this stage that both of her feet were "floppy." She was using a walking frame by age 18 months but never achieved independent walking. At age 3 years, she had reduced tone in the limbs, absent tendon reflexes, and distal muscle weakness and wasting in the legs and hands. Proximal muscle strength was preserved. Results of motor nerve conduction velocities and sensory studies were normal, and EMG and muscle biopsy were consistent with denervation due to anterior horn cell degeneration. SMN1 gene testing results were normal. By age 7 years, her condition had progressed with marked distal weakness and wasting in the legs (figure) and additionally hip extension (Medical Research Council [MRC] Grade 2) and flexion (MRC Grade 3). Wasting and weakness of the small muscles of the hand (figure) was associated with impaired finger grip. There was mild weakness of eye closure and a weak cough, and her voice was decreased in volume, but there was no tongue wasting. She was using accessory muscles of respiration, and forced vital capacity was reduced to 80% predicted, with no overt diaphragmatic weakness. Bilateral leg flexion contractures had developed at the hip, and she had a marked lumbar lordosis and scoliosis (figure). Both parents were healthy and did not carry the mutation, which we presume arose de novo in the proband.
Family 2: S581L (2260c¡t). The proband is a woman who presented to orthopedic services at age 27 years with foot deformity that began in late adolescence. Referral to a neurologist and subsequent neurophysiologic analysis led to a diagnosis of CMT2. There is an extensive family history spanning four generations, including the proband's grandmother, who is still alive at age 97 years. At the time of her own diagnosis, she became aware that her 4-yearold son was affected because of uneven wearing of the soles of his shoes and a mildly abnormal gait. Despite this, he was able to participate in sport at school. By age 13 years, his foot deformity required surgical intervention, and throughout adolescence, his gait deteriorated. Now aged 30 years, he can walk and manage stairs slowly, but he trips frequently. Both mother and son have severe distal weakness (MRC Grade 2 to 3) and wasting, more severe in the lower than upper limb, and areflexia and reduced vibration and joint position sense at the ankles, consistent with a diagnosis of CMT2.
Family 3: I280F (1358a¡t). The proband is a woman now aged 34 years who presented to an orthopedic surgeon at age 11 years with bilateral weakness of the feet. At presentation, there was wasting of the first dorsal interossei. Her father, grandfather, and two siblings were also affected with an age at onset from the mid-teens. Her son presented with foot drop and mild hand-grip weakness at age 11, associated with wasting of the hands and pes cavus. Sensory testing was clinically and neurophysiologically normal, but compound muscle action potential amplitudes were reduced by 20% in the upper limb and 50% in the lower limb. Both individuals are ambulant, with occasional falls.
Discussion. The spinal muscular atrophies, or hereditary motor neuronopathies, are a clinically and genetically heterogeneous group of disorders characterized by primary degeneration of the anterior horn cells of the spinal cord and sometimes of the bulbar motor nuclei. The distal forms are said to account for 10% of SMA 4 but in our experience are commoner. Distal HMN Type V, with a characteristic picture of onset in adolescence, slow progression, and predominant upper limb involvement, and CMT2D, a similar disorder with minor sensory involvement, are allelic disorders due to mutations in the gene for glycyltRNA synthetase. 2, 3, 5 In this study, we screened a highly heterogeneous population of patients with inherited and sporadic forms of lower motor neuron degeneration to determine whether GARS mutations cause a broader phenotype than previously described. We have identified three new mutations. One family carrying an I280F mutation has a phenotype consistent with previously described dHMNV families, with onset at age 11 years and early upper limb involvement. In contrast, two further families with mutations in the anticodon binding domain presented with predominant lower limb involvement in infancy or early childhood. In particular, we identified a de novo dominant G598A mutation located in the center of the anticodon binding domain, associated with a severe form of infantile SMA affecting the lower limbs more severely, with failure to acquire ambulation and associated respiratory and facial muscle involvement.
Previously reported mutations (see table) cluster around residues of the catalytic core 2 and are expected to affect the enzyme kinetics, although this remains to be formally demonstrated. The anticodon binding domain is important for discriminating the correct tRNA to ligate with glycine. Human GARS is a homodimer, and it possible that the G598A mutation exerts a dominant negative effect severely reducing enzymatic activity, or that phenotypic severity correlates with functions other than enzyme efficiency. The specificity of motor neuron degeneration due to mutations in glycyl-tRNA synthetase is unexplained. Aminoacyl-tRNA synthetases have a ubiquitous cellular expression and are considered to be among the most phylogenetically ancient of proteins, with a pivotal role in ensuring the strict fidelity of translation of the genetic code to protein by ligating amino acids to their cognate tRNA. GARS is unusual among the synthetases in that the mitochondrial and cytoplasmic enzymes are encoded by the same gene with two alternative translation starts. Aminoacyl-tRNA synthetases also have important noncanonical functions, including cell-cycle regulation and signal transduction, 6 which are often idiosyncratic to a particular ARS, suggesting that these enzymes have been repeatedly targeted for evolutionary adaptation. Specifically, GARS has been shown to participate in 3= end mRNA formation in yeast. 7 The recent identification of mutations in tyrosyl-tRNA synthetase in patients with an axonal form of CMT 8 suggests that these proteins may share a noncanonical neuron-specific function in cell maintenance. 
